Article Abstract

Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer?

Authors: Andrea Bianco, Susan F. M. Campbell


Targeting adaptive immunity is a game changer for cancer treatment, revolutionizing lung cancer management. Chemotherapy has been the standard treatment for lung cancer (1-4) until recently when molecular targets including genes harbouring cancer-driving mutations and immune check-points have emerged as targets for new therapies (5-12). With the increasing relevance of ICIs, clinical research is required to define which combination regimens provide the greatest benefits in lung cancer patients.